Home › Companies › Neumora Therapeutics, Inc. › 2025-2026
At Neumora Therapeutics, Inc.'s shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 77 asset managers reported how they voted in their SEC Form N-PX filings, covering 415 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Neumora Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED… — the reporting funds and managers cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Neumora Therapeutics, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 27, 2026: 6 items on Neumora Therapeutics, Inc.’s Form 8-K, filed May 29, 2026: 6 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Neumora Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Neumora Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Paul L. Berns | 126,617,746 | -- | -- | 6,076,577 | 25,026,919 | 95% | Not verified | — |
| Elect Director: Matthew Fust | 125,242,046 | -- | -- | 7,452,277 | 25,026,919 | 94% | Not verified | — |
| Elect Director: David Piacquad | 126,878,899 | -- | -- | 5,815,424 | 25,026,919 | 96% | Not verified | — |
| 2. The ratification of the selection by the audit committee of the board of directors of the Company (the "Board") of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 | 157,623,815 | 53,613 | 43,814 | -- | -- | 99.9% | Not verified | — |
| 3. Advisory vote on the compensation of the Company's named executive officers | 131,998,871 | 420,917 | 274,535 | -- | 25,026,919 | 99.6% | Not verified | — |
| 4. Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers | 124,682,414 | -- | 39,349 | -- | 25,026,919 | — | Not verified | — |
Source: Neumora Therapeutics, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.
Each item below shows how the 77 asset managers that disclosed a Neumora Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Neumora Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: David Piacquad
Neumora Therapeutics, Inc.’s own tally for this item (“Elect Director: David Piacquad”): 126,878,899 for, 5,815,424 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 6,662,460 for, 431,282 withheld, 13 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,034,541 | 0 | 13 | 0 | For |
| Fidelity | 860,496 | 0 | 0 | 0 | For |
| BlackRock | 541,065 | 0 | 0 | 0 | For |
| Charles Schwab | 516,525 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 225,000 | Withhold |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 186,984 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 113,175 | Withhold |
| American Century | 0 | 0 | 0 | 40,728 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 18,400 | Withhold |
| Jackson National | 0 | 0 | 0 | 17,301 | Withhold |
| ProShares | 0 | 0 | 0 | 7,475 | Withhold |
| Victory Capital | 0 | 0 | 0 | 6,372 | Withhold |
| Goldman Sachs | 3,032 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 2,831 | Withhold |
| Advisors' Inner Circle Fund III | 481 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Matthew Fust
Neumora Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew Fust”): 125,242,046 for, 7,452,277 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 6,121,391 for, 972,347 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,034,537 | 0 | 17 | 0 | For |
| Fidelity | 860,496 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 541,065 | Withhold |
| Charles Schwab | 516,525 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 225,000 | Withhold |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 186,984 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 113,175 | Withhold |
| American Century | 0 | 0 | 0 | 40,728 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 18,400 | Withhold |
| Jackson National | 0 | 0 | 0 | 17,301 | Withhold |
| ProShares | 0 | 0 | 0 | 7,475 | Withhold |
| Victory Capital | 0 | 0 | 0 | 6,372 | Withhold |
| Goldman Sachs | 3,032 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 2,831 | Withhold |
| Advisors' Inner Circle Fund III | 481 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Paul Berns
Neumora Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul L. Berns”): 126,617,746 for, 6,076,577 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 6,662,459 for, 431,282 withheld, 14 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,034,540 | 0 | 14 | 0 | For |
| Fidelity | 860,496 | 0 | 0 | 0 | For |
| BlackRock | 541,065 | 0 | 0 | 0 | For |
| Charles Schwab | 516,525 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 225,000 | Withhold |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 186,984 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 113,175 | Withhold |
| American Century | 0 | 0 | 0 | 40,728 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 18,400 | Withhold |
| Jackson National | 0 | 0 | 0 | 17,301 | Withhold |
| ProShares | 0 | 0 | 0 | 7,475 | Withhold |
| Victory Capital | 0 | 0 | 0 | 6,372 | Withhold |
| Goldman Sachs | 3,032 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 2,831 | Withhold |
| Advisors' Inner Circle Fund III | 481 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 17 managers: 6,955,883 1 year, 130,476 3 year, 7,396 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| SOFTBANK GROUP CORP. | 0 | 0 | 0 | 0 | -- |
| PERCEPTIVE ADVISORS LLC | 4,288,471 | 0 | 0 | 0 | For |
| Exor N.V. | 4,215,662 | 0 | 0 | 0 | For |
| Impresa Management LLC | 3,487,100 | 0 | 0 | 0 | For |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| CANADA PENSION PLAN INVESTMENT BOARD | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 69 managers: 11,991,233 for, 22 not voted, 29,073,964 1 year, 107,450 3 year, 80,000 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,034,553 | 1 | 0 | 0 | For |
| Fidelity | 860,496 | 0 | 0 | 0 | For |
| BlackRock | 541,065 | 0 | 0 | 0 | For |
| Charles Schwab | 516,525 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 225,000 | 0 | 0 | 0 | For |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 186,984 | 0 | 0 | 0 | For |
| Dimensional | 113,175 | 0 | 0 | 0 | For |
| American Century | 40,728 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 18,400 | 0 | 0 | 0 | For |
| Jackson National | 17,301 | 0 | 0 | 0 | For |
| ProShares | 7,475 | 0 | 0 | 0 | For |
| Victory Capital | 6,372 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,032 | 0 | 0 | 0 | For |
| John Hancock | 2,831 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 481 | 0 | 0 | Against |
Fund voting reports, all 17 managers: 7,093,273 for, 482 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Siren, L.L.C. | 8,495,648 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 4,288,471 | 0 | 0 | 0 | For |
| Exor N.V. | 4,215,662 | 0 | 0 | 0 | For |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3,309,123 | 0 | 0 | 0 | For |
| Two Sigma | 1,256,359 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,062,087 | 0 | 0 | 0 | For |
| BlackRock | 1,030,988 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 1,013,968 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 999,170 | 0 | 0 | 0 | For |
| Vanguard | 613,638 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 575,352 | 0 | 0 | 0 | For |
| Point72 | 521,047 | 0 | 0 | 0 | For |
| Charles Schwab | 516,596 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 511,084 | 0 | 0 | 0 | For |
| Renaissance | 507,760 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 305,962 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,578 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 225,000 | 0 | 0 | 0 | For |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| Northern Trust | 196,881 | 0 | 0 | 0 | For |
| Citadel | 188,894 | 0 | 0 | 0 | For |
| CANADA PENSION PLAN INVESTMENT BOARD | 168,300 | 0 | 0 | 0 | For |
| State Street | 152,803 | 0 | 0 | 0 | For |
| Dimensional | 107,450 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 31,768,032 for, 7,214 against, 22 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT, BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, OF ERNST & YOUNG LLP, AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND INDEPENDENT AUDITOR OF THE COMPANY FOR THE YEAR ENDING DECEMBER 31, 2026.
Neumora Therapeutics, Inc.’s own tally for this item (“2. The ratification of the selection by the audit committee of the board of directors of the Company (the "Board") of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal y”): 157,623,815 for, 53,613 against, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 7,093,755 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,034,554 | 0 | 0 | 0 | For |
| Fidelity | 860,496 | 0 | 0 | 0 | For |
| BlackRock | 541,065 | 0 | 0 | 0 | For |
| Charles Schwab | 516,525 | 0 | 0 | 0 | For |
| Federated Hermes | 314,119 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 225,000 | 0 | 0 | 0 | For |
| Invesco | 205,217 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 186,984 | 0 | 0 | 0 | For |
| Dimensional | 113,175 | 0 | 0 | 0 | For |
| American Century | 40,728 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 18,400 | 0 | 0 | 0 | For |
| Jackson National | 17,301 | 0 | 0 | 0 | For |
| ProShares | 7,475 | 0 | 0 | 0 | For |
| Victory Capital | 6,372 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,032 | 0 | 0 | 0 | For |
| John Hancock | 2,831 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 481 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 185,284,244 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.18% |
| 2 | Fidelity | 0.46% |
| 3 | BlackRock | 0.29% |
| 4 | Charles Schwab | 0.28% |
| 5 | Federated Hermes | 0.17% |
| 6 | BRIDGEWAY FUNDS INC | 0.12% |
| 7 | Invesco | 0.11% |
| 8 | FRANKLIN STRATEGIC SERIES | 0.10% |
| 9 | Dimensional | 0.06% |
| 10 | American Century | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Siren, L.L.C. | 4.59% |
| 2 | SOFTBANK GROUP CORP. | 3.29% |
| 3 | PERCEPTIVE ADVISORS LLC | 2.31% |
| 4 | Exor N.V. | 2.28% |
| 5 | Impresa Management LLC | 1.88% |
| 6 | WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 1.79% |
| 7 | Two Sigma | 0.68% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.57% |
| 9 | BlackRock | 0.56% |
| 10 | MARSHALL WACE, LLP | 0.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Amgen Inc. | 19.09% | DEF14A |
| Kristina Burow | 18.29% | DEF14A |
| ARCH Venture Fund VII, L.P. | 18.27% | 13D |
| Entities Affiliated with ARCH Venture Partners | 18.27% | DEF14A |
| Raymond Debbane | 4.59% | 13G |
| Paul L. Berns | 4.16% | DEF14A |
| K2 HealthVentures Equity Trust LLC | 3.13% | 13G |
| Vanguard Group | 2.45% | 13F |
| FMR (Fidelity) | 1.89% | 13F |
| Millennium Management | 1.49% | 13F |
Percentages above are of 185,284,244 shares outstanding, as reported by Neumora Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Neumora Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Neumora Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Neumora Therapeutics (NMRA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/neumora-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.